Amelioration of Experimental Autoimmune Encephalomyelitis Using the Myelin Oligodendrocyte Glycoprotein35-85 Peptide
| dc.contributor.advisor | Jeri-Anne Lyons | |
| dc.contributor.committeemember | Jeri-Anne Lyons | |
| dc.contributor.committeemember | Dean Nardelli | |
| dc.contributor.committeemember | Douglas Steeber | |
| dc.creator | Agashe, Vrushali Vinay | |
| dc.date.accessioned | 2025-01-16T19:53:42Z | |
| dc.date.available | 2025-01-16T19:53:42Z | |
| dc.date.issued | 2012-12-01 | |
| dc.description.abstract | Multiple sclerosis (MS) is a chronic debilitating disease affecting the central nervous system (CNS) in humans. Experimental autoimmune encephalomyelitis (EAE) remains the primary animal model of MS. MS/EAE are considered to be autoimmune diseases mediated by CD4+ T helper (TH) cells. The role of B cells and antibody is under debate. Previous studies established B cell dependent (induced with recombinant myelin oligodendrocyte glycoprotein, [rMOG]) and B cell independent (induced with the MOG35-55 peptide) animal models of EAE. The identification of a unique B cell epitope (MOG amino acids [aa] 46-85) preceding the identified protective epitope (MOG61-85) led to the hypothesis that these antibodies against MOGaa46-85 were important in epitope selection in the rMOG model of EAE. Co-immunization of WT and B cell deficient (B cell-/-) mice with MOG35-55 and MOG61-85 resulted in abrogation (B cell-/- mice) or amelioration (WT mice) of EAE. Thus, mice were immunized with MOG35-85 peptide and observed for EAE induction. Absence of EAE in WT and B cell-/- mice was observed. These results confirmed the protective nature of the MOG61-85 peptide but did not support a role for antibodies to MOG¬46-85 in the selection of the protective epitope. Mechanistic studies revealed decreased production of the pro-inflammatory cytokines, interferon (INF) γ and interleukin (IL) 17, when immune cells were primed to MOG61-85 in vivo. Furthermore, using IL10 deficient (IL10-/-) mice, it was demonstrated that IL10 was important in EAE incidence, but not in disease severity, in the presence of the MOG61-85 epitope. Flow cytometric analysis of spleen cells from these mice demonstrated an increase in the number of T cells expressing FoxP3 expression and an increase in the CD4+ CD25+ T cell population, but a comparable level of CD4+ T regulatory (Treg) cell population. In addition no changes could be detected in the CD8+ T cell population. These experiments provide a deeper understanding of the B cell-dependent, rMOG model of EAE, demonstrating the role of the MOG61-85 epitope in down-regulating the pro-inflammatory response leading to protection from EAE, perhaps mediated by CD4+ Treg cells. | |
| dc.identifier.uri | http://digital.library.wisc.edu/1793/88611 | |
| dc.relation.replaces | https://dc.uwm.edu/etd/73 | |
| dc.subject | B Cells and Antibody | |
| dc.subject | Experimental Autoimmune Encephalomyelitis | |
| dc.subject | Multiple Sclerosis | |
| dc.title | Amelioration of Experimental Autoimmune Encephalomyelitis Using the Myelin Oligodendrocyte Glycoprotein35-85 Peptide | |
| dc.type | thesis | |
| thesis.degree.discipline | Biomedical Sciences | |
| thesis.degree.grantor | University of Wisconsin-Milwaukee | |
| thesis.degree.name | Master of Science |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Agashe_uwm_0263m_10057.pdf
- Size:
- 1.28 MB
- Format:
- Adobe Portable Document Format
- Description:
- Main File